Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study

Fangwen Zou; David Faleck; Anusha Thomas; Jessica Harris; Deepika Satish; Xuemei Wang; Aline Charabaty; Marc S Ernstoff; Isabella C Glitza Oliva; Stephen Hanauer; Jennifer McQuade; Michel Obeid; Amishi Shah; David M Richards; Elad Sharon; Jedd Wolchok; John Thompson; Yinghong Wang

doi:10.1136/jitc-2021-003277

Article info

PDF

PDF +
Supplementary
Material

Clinical/translational cancer immunotherapy

Original research

Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study

Authors

Fangwen Zou Department of Oncology, Second Xiangya Hospital, Changsha, Hunan, ChinaDepartment of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
David Faleck Department of Gastroenterology, Hepatology and Nutrition, Memorial Sloan Kettering Cancer Center, New York, New York, USA PubMed articles Google scholar articles
Anusha Thomas Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Jessica Harris Department of Gastroenterology, Hepatology and Nutrition, Memorial Sloan Kettering Cancer Center, New York, New York, USA PubMed articles Google scholar articles
Deepika Satish Department of Gastroenterology, Hepatology and Nutrition, Memorial Sloan Kettering Cancer Center, New York, New York, USA PubMed articles Google scholar articles
Xuemei Wang Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Aline Charabaty Department of Gastroenterology, Johns Hopkins University, Washington, DC, USA PubMed articles Google scholar articles
Marc S Ernstoff Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA PubMed articles Google scholar articles
Isabella C Glitza Oliva Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Stephen Hanauer Department of Medicine, Northwestern University, Chicago, Illinois, USA PubMed articles Google scholar articles
Jennifer McQuade Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Michel Obeid Department of Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland PubMed articles Google scholar articles
Amishi Shah Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
David M Richards Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Elad Sharon Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA PubMed articles Google scholar articles
Jedd Wolchok Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA PubMed articles Google scholar articles
John Thompson University of Washington, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA PubMed articles Google scholar articles
Yinghong Wang Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles

Citation

Zou F, Faleck D, Thomas A, et al

Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study

Journal for ImmunoTherapy of Cancer 2021;9:e003277. doi: 10.1136/jitc-2021-003277

Online issue publication

May 08, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password